» Articles » PMID: 39242486

A Fluorescent Probe for Monitoring Carboxylesterases in Pulmonary Cells Under Permissive Hypercapnia Condition

Overview
Journal Anal Sci
Publisher Springer
Specialty Chemistry
Date 2024 Sep 6
PMID 39242486
Authors
Affiliations
Soon will be listed here.
Abstract

Herein, by combining the benzofuranone-derived fluorophore and the carbamate recognition group, a fluorescent probe named BFO-CarE was developed for monitoring the carboxylesterase (CarE) level in pulmonary cells under the permissive hypercapnia condition. It showed a notable fluorescence response towards CarE at 570 nm under the excitation of 510 nm. The in-solution tests revealed the advantages of BFO-CarE including high sensitivity, high specificity, relatively rapid response, and high steadiness. It was also low-toxic upon the pulmonary cell lines. During the intracellular imaging in pulmonary cells, BFO-CarE achieved the monitoring of the CarE level in both inhibition and activation status. In particular, BFO-CarE realized the visualization of the affection of the permissive hypercapnia condition on the CarE level, which indicated the hypoxia tolerance of CarE. This work was informative for investigating the impact of hypoxia in pulmonary cells, and the corresponding anaesthesia-related approaches.

References
1.
Wang D, Zou L, Jin Q, Hou J, Ge G, Yang L . Human carboxylesterases: a comprehensive review. Acta Pharm Sin B. 2018; 8(5):699-712. PMC: 6146386. DOI: 10.1016/j.apsb.2018.05.005. View

2.
Lian J, Nelson R, Lehner R . Carboxylesterases in lipid metabolism: from mouse to human. Protein Cell. 2017; 9(2):178-195. PMC: 5818367. DOI: 10.1007/s13238-017-0437-z. View

3.
Redinbo M, Potter P . Mammalian carboxylesterases: from drug targets to protein therapeutics. Drug Discov Today. 2005; 10(5):313-25. DOI: 10.1016/S1359-6446(05)03383-0. View

4.
Gan C, Wang J, Martinez-Chavez A, Hillebrand M, de Vries N, Beukers J . Carboxylesterase 1 family knockout alters drug disposition and lipid metabolism. Acta Pharm Sin B. 2023; 13(2):618-631. PMC: 9978993. DOI: 10.1016/j.apsb.2022.10.017. View

5.
Abozaid Y, Ayada I, van Kleef L, Vallerga C, Pan Q, Brouwer W . Plasma proteomic signature of fatty liver disease: The Rotterdam Study. Hepatology. 2023; 78(1):284-294. DOI: 10.1097/HEP.0000000000000300. View